Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | General Counsel and Secretary | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 94,784 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 1,990 · Balance 96,774 Row 2 · 2026-10-06 · Sale · Disposed 1,990 · Balance 94,784 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.62 · Expires 2027-05-31 | Direct | 81,242 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 1,990 · Balance 81,242 F3: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2021 Filed Jan 20, 2021 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 8,997 | $205.60 | $1,849,783.20 |
DisclosureSEC source: 0001209191-21-004452 · doc4.xml · nonDerivative · entry 4 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,331 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.00 to $205.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 7,818 | $204.40 | $1,597,999.20 |
DisclosureSEC source: 0001209191-21-004452 · doc4.xml · nonDerivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,328 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.00 to $204.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,785 | $203.58 | $1,381,290.30 |
DisclosureSEC source: 0001209191-21-004452 · doc4.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,146 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.00 to $203.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 27,500 | $51.49 | $1,415,975.00 |
DisclosureSEC source: 0001209191-21-004452 · doc4.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (right to buy) · Derivative | 22,026 | $0.00 Strike: $13.62 | $0.00 |
DisclosureSEC source: 0001209191-20-062720 · doc4.xml · derivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,974 Underlying: Common Shares · 22,026 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% vested on May 31, 2018 and the remaining 75% vests monthly thereafter for 36 months. Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 22,026 | $13.62 | $299,994.12 |
DisclosureSEC source: 0001209191-20-062720 · doc4.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 389 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 21:34 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 11,666 | $0.00 Strike: $86.75 | $0.00 |
DisclosureSEC source: 0001209191-20-054064 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,666 Underlying: Common Shares · 11,666 shares Expires 2030-10-05 F1 · derivative.exercise_date: This option was granted on October 5, 2020 with respect to 11,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 5, 2020. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018492 · doc4.xml · derivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Shares · 8,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $44.67 | $0.00 |
DisclosureSEC source: 0001209191-20-018492 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 35,000 shares Expires 2030-03-10 F1 · derivative.exercise_date: This option was granted on March 10, 2020 with respect to 35,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059276 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-049322 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest in full on September 10, 2021, subject to continued employment with the company. F2 · derivative.expiration_date: The restricted stock units shall vest in full on September 10, 2021, subject to continued employment with the company. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $40.87 | $0.00 |
DisclosureSEC source: 0000899243-19-006652 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2029-03-05 F1 · derivative.exercise_date: This option was granted on March 5, 2019 with respect to 65,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016879 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Shares · 32,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 32,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 21:50 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $51.49 | $0.00 |
DisclosureSEC source: 0000899243-18-006955 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This option was granted on March 7, 2018 and shall vest in 48 equal monthly installments. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Options (Right to Buy) · Derivative | 123,000 | $0.00 Strike: $13.62 | $0.00 |
DisclosureSEC source: 0000899243-17-015163 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,000 Underlying: Common Shares · 123,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.